Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine and ERAS in Pancreatic Cancer Surgery
NCT05470166Completed
- Sponsor
- Alexandria University
- Start
- Apr 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in pancreatic cancer (PC) comparing Lidocaine Group with Placebo Group (2 arms). Primary endpoint: Post-operative nociceptive pain assessment at 24 hours. Started Apr 2022; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05470166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470166.